



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C07D 239/18, A61K 31/505, 239/14 C07D 233/52, 233/48, A01N 43/54, A61K 31/415, A01N 43/50	A1	(11) International Publication Number: WO 92/14704 (43) International Publication Date: 3 September 1992 (03.09.92)
(21) International Application Number: PCT/US92/01033 (22) International Filing Date: 7 February 1992 (07.02.92) (30) Priority data: 652,575 8 February 1991 (08.02.91) US (71) Applicants: THE ROCKEFELLER UNIVERSITY [US/ US]; 1230 York Avenue, New York, NY 10021-6399 (US). ALTEON INC. [US/US]; 165 Ludlow Street, North- vale, NJ 07647 (US). (72) Inventors: ULRICH, Peter, C. ; 148 De Wolf Road, Old Tappan, NJ 07675 (US). CERAMI, Anthony ; Ram Is- land Drive, Shelter Island, NY 10977 (US). (74) Agent: JACKSON, David, A.; Klauber & Jackson, 411 Hackensack Avenue, Hackensack, NJ 07601 (US).		(81) Designated States: AT (European patent), AU, BE (Euro- pean patent), CA, CH (European patent), DE (Euro- pean patent), DK (European patent), ES (European pa- tent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), MC (European patent), NL (Euro- pean patent), SE (European patent). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: 2-SUBSTITUTED-2-IMIDAZOLINES (57) Abstract The present invention relates to compositions and methods for inhibiting nonenzymatic cross-linking (protein aging) which contain novel 2-substituted-2-imidazolines. Accordingly, a composition is disclosed which comprises an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

2-SUBSTITUTED-2-IMIDAZOLINESRELATED PUBLICATIONS

- 5 The Applicants are co-authors of the following articles directed to the subject matter of the present invention: "COVALENT ATTACHMENT OF SOLUBLE PROTEINS BY NONENZYMATICALLY GLYCOSYLATED COLLAGEN: ROLE IN THE IN SITU FORMATION OF IMMUNE COMPLEXES", Brownlee et al., J. Exp. Med., 158, pp. 1730-1744 (1983); and "AGING OF
- 10 PROTEINS: ISOLATION AND IDENTIFICATION OF FLUORESCENT CHROMOPHORE FROM THE REACTION OF POLYPEPTIDES WITH GLUCOSE", Pongor et al., Proc. Natl. Acad. Sci. USA, 81, pp. 2684-2688, (1984), and "ADVANCED GLYCOSYLATION
- 15 ENDPRODUCTS IN TISSUE AND THE BIOCHEMICAL BASIS OF DIABETIC COMPLICATIONS", Brownlee et al., The New Eng. J. of Med., 318, pp. 1315-1321 (1988). All of the above publications are incorporated herein by reference.

20

BACKGROUND OF THE INVENTION

- The present invention relates generally to the aging of proteins resulting from their reaction with glucose and other reducing sugars, and more particularly to the
- 25 inhibition of the reaction of nonenzymatically glycosylated proteins and the often resultant formation of advanced glycosylation endproducts and cross-links.

- The reaction between glucose and proteins has been known
- 30 for some time. Its earliest manifestation was in the appearance of brown pigments during the cooking of food, which was identified by Maillard in 1912, who observed that glucose or other reducing sugars react with amino acids to form adducts that undergo a series of
- 35 dehydrations and rearrangements to form stable brown pigments. Maillard, C.R. Acad. Sci., 154, pp. 66-68, (1912). Further studies have suggested that stored and heat treated foods undergo nonenzymatic browning as a

result of the reaction between glucose and the polypeptide chain, and that the proteins are resultingly cross-linked and correspondingly exhibit decreased bioavailability.

5

This reaction between reducing sugars and food proteins was found to have its parallel in vivo. Thus, the nonenzymatic reaction between glucose and the free amino groups on proteins to form a stable, 1-deoxyketosyl
10 adduct, known as the Amadori product, has been shown to occur with hemoglobin, wherein a rearrangement of the amino terminal of the beta-chain of hemoglobin by reaction with glucose, forms the adduct known as hemoglobin A_{1c}. The reaction has also been found to
15 occur with a variety of other body proteins, such as lens crystallins, collagen and nerve proteins. See, Bunn et al., Biochem. Biophys. Res. Comm., 67, pp. 103-109 (1975); Koenig et al., J. Biol. Chem., 252, pp. 2992-2997 (1977); Monnier et al., in Maillard Reaction in Food and
20 Nutrition, ed. Waller, G.A., American Chemical Society, 215, pp.431-448 (1983); and Monnier and Cerami, Clinics in Endocrinology and Metabolism, 11, pp. 431-452 (1982).

Moreover, brown pigments with spectral and fluorescent
25 properties similar to those of late-stage Maillard products have also been observed in vivo in association with several long-lived proteins, such as lens proteins and collagen from aged individuals. An age-related linear increase in pigment was observed in human dura
30 collagen between the ages of 20 to 90 years. See, Monnier et al., Science, 211, pp. 491-493 (1981); Monnier et al., Biochem. Biophys. Acta, 760, pp. 97-103 (1983); and, Monnier et al., Proc. Natl. Acad. Sci., 81, pp. 583-587 (1984). Interestingly, the aging of collagen can be
35 mimicked in vitro by the cross-linking induced by glucose; and the capture of other proteins and the formation of adducts by collagen, also noted, is

theorized to occur by a cross-linking reaction, and is believed to account for the observed accumulation of albumin and antibodies in kidney basement membrane. See, Brownlee et al, J. Exp. Med., 158, pp. 1739-1744 (1983);
5 and Kohn et al., Diabetes, 33, No. 1, pp. 57-59 (1984).

In Parent Application Serial No. 798,032, a method and associated agents were disclosed that served to inhibit the formation of advanced glycosylation endproducts by
10 reacting with the early glycosylation product that results from the original reaction between the target protein and glucose. Accordingly, inhibition was postulated to take place as the reaction between the inhibitor and the early glycosylation product appeared to
15 interrupt the subsequent reaction of the glycosylated protein with additional protein material to form the cross-linked late stage product. One of the agents identified as an inhibitor was aminoguanidine, and the results of further testing have borne out its efficacy in
20 this regard.

While the success that has been achieved with aminoguanidine and similar compounds is promising, a need continues to exist to identify and develop additional
25 inhibitors that broaden the availability and perhaps the scope of this potential activity and its diagnostic and therapeutic utility.

SUMMARY OF THE INVENTION


30

In accordance with the present invention, a method and compositions are disclosed for the inhibition of the advanced glycosylation of proteins (protein aging). In particular, the compositions comprise agents for
35 inhibiting nonenzymatic cross-linking (protein aging) due to the formation of advanced glycosylation endproducts. The agents may be selected from those materials capable

of reacting with the early glycosylation product from the reaction of glucose with proteins and preventing further reactions. Cross-linking caused by other reactive sugars present in vivo or in foodstuffs, including ribose, galactose and fructose would also be prevented by the methods and compositions of the present invention.

The agents comprise compounds having the following structural formula:

10



15

wherein

20

n is 1 or 2;

R_1 is an amino group or a hydroxyethyl group; and

R_2 is an amino, a hydroxyalkylamino, a lower alkyl group or a group of the formula

alk-Y

25

wherein alk is a lower alkylene group and Y is selected from the group consisting of hydroxy, lower alkoxy, lower alkylthio, lower alkylamino and heterocyclic groups containing 4-7 ring members and 1-3 heteroatoms;

30

with the proviso that when R_1 is a hydroxyethyl group then R_2 is an amino group; their biocompatible and pharmaceutically acceptable acid addition salts, and mixtures thereof; and a carrier therefor.

35

The compounds utilized in the compositions of this invention appear to react with the early glycosylation product thereby preventing the same from later forming the advanced glycosylation end products which lead to protein cross-links, and thereby, to protein aging.

40

The present invention also relates to a method for inhibiting protein aging by contacting the initially glycosylated prot in at th stage of the arly glycosylation product with a quantity of one or more of
5 the agents of the present invention, or a composition containing the same. In the instance where the present method has industrial application, one or more of the agents may be applied to the proteins in question, either by introduction into a mixture of the same in the
10 instance of a protein extract, or by application or introduction into foodstuffs containing the protein or proteins, all to prevent premature aging and spoilage of the particular foodstuffs.

15 The ability to inhibit the formation of advanced glycosylation endproducts carries with it significant implications in all applications where protein aging is a serious detriment. Thus, in the area of food technology, the retardation of food spoilage would confer an obvious
20 economic and social benefit by making certain foods of marginal stability less perishable and therefore more available for consumers. Spoilage would be reduced as would the expense of inspection, removal, and replacement, and the extended availability of the foods
25 could aid in stabilizing their price in the marketplace. Similarly, in other industrial applications where the perishability of proteins is a problem, the admixture of the agents of the present invention in compositions containing such proteins would facilitate the extended
30 useful life of the same. Presently used food preservatives and discoloration preventatives such as sulfur dioxide, known to cause toxicity including allergy and asthma in animals, can be replaced with compounds such as those described herein.

35

The present method has particular therapeutic application as the Maillard process acutely affects several of the

significant protein masses in the body, among them collagen, elastin, lens proteins, and the kidney glomerular basement membranes. These proteins deteriorate both with age (hence the application of the
5 term "protein aging") and a consequence of diabetes. Accordingly, the ability to either retard or substantially inhibit the formation of advanced glycosylation endproducts carries the promise of treatment for diabetes and of course, improving the
10 quality and, perhaps, duration of animal life.

The present agents are also useful in the area of personal appearance and hygiene, as they prevent the staining of teeth by cationic anti-microbial agents with
15 anti-plaque properties, such as chlorhexidine.

Accordingly, it is a principal object of the present invention to provide a method for inhibiting the extensive cross-linking of proteins that occurs as an
20 ultimate consequence of the reaction of the proteins with glucose and other reactive sugars, by correspondingly inhibiting the formation of advanced glycosylation endproducts.

25 It is a further object of the present invention to provide a method as aforesaid which is characterized by a reaction with an initially glycosylated protein identified as an early glycosylation product.

30 It is a further object of the present invention to provide a method as aforesaid which prevents the rearrangement and cross-linking of the said early glycosylation products to form the said advanced glycosylation endproducts.

35

It is a yet further object of the present invention to provide agents capable of participating in the reaction

with the said early glycosylation products in the method as afor said.

It is a still further object of the present invention to
5 provide therapeutic methods of treating the adverse consequences of protein aging by resort to the aforesaid method and agents.


It is a still further object of the present invention to
10 provide a method of inhibiting the discoloration of teeth by resort to the aforesaid method and agents.

It is a still further object of the present invention to provide compositions including pharmaceutical
15 compositions, all incorporating the agents of the present invention.

Other objects and advantages will become apparent to those skilled in the art from a consideration of the
20 ensuing description.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

In accordance with the present invention, agents,
25 compositions including pharmaceutical compositions containing said agents and associated methods have been developed which are believed to inhibit the formation of advanced glycosylation endproducts in a number of target proteins existing in both animals and plant material. In
30 particular, the invention relates to a composition which may contain one or more agents comprising compounds having the structural formula



wherein

n is 1 or 2;

R₁ is an amino group or a hydroxyethyl group; and

5 R₂ is an amino, a hydroxyalkylamino, a lower alkyl group or a group of the formula

alk-Y

wherein alk is a lower alkylene group and Y is selected from the group consisting of hydroxy, lower
10 alkoxy, lower alkylthio, lower alkylamino and heterocyclic groups containing 4-7 ring members and 1-3 heteroatoms;

with the proviso that when R₁ is a hydroxyethyl group then R₂ is an amino group; their biocompatible and
15 pharmaceutically acceptable acid addition salts, and mixtures thereof; and a carrier therefor.

The lower alkyl, lower alkylene and lower alkoxy groups referred to herein contain 1-6 carbon atoms and include
20 methyl, methylene, methoxy, ethyl, ethylene, ethoxy, propyl, propylene, propoxy, butyl, butylene, butoxy, pentyl, pentylene, pentyloxy, hexyl, hexylene, hexyloxy and the corresponding branched chain isomers thereof. The heterocyclic groups referred to herein include 4-7
25 membered rings having at least one and up to 3 heteroatoms therein. Representative heterocyclic groups are those such as morpholino, piperidino, piperazino, methylpiperazino, and hexamethylenimino.

30 Equivalent to the compounds of Formula I for the purpose of this invention are the biocompatible and pharmaceutically acceptable salts thereof. Such salts can be derived from a variety of organic and inorganic acids including but not limited to methanesulfonic,
35 hydrochloric, toluenesulfonic, sulfuric, maleic, acetic and phosphoric acids.

Of the compounds encompassed by Formula I, certain combinations of substituents are preferred. For instance, when R_1 is a hydroxyethyl group, then R_2 is an amino group. When R_1 is an amino group, then R_2 is preferably a hydroxy lower alkylamino, a lower alkyl group or a group of the formula alk-Y , wherein alk is a lower alkylene group and Y is selected from the group consisting of hydroxy, lower alkoxy, lower alkylthio, lower alkylamino and heterocyclic groups containing 4-7 ring members and 1-3 heteroatoms.

Representative compounds of the present invention are:
1-amino-2-[2-(2-hydroxyethyl)hydrazino]-2-imidazoline;
1-amino-2-(2-hydroxyethylamino)-2-imidazoline;
15 1-(2-hydroxyethyl)-2-hydrazino-1,4,5,6-tetrahydropyrimidine;
1-(2-hydroxyethyl)2-hydrazino-2-imidazoline;
1-amino-2-([2-(4-morpholino)ethyl]amino)imidazoline;
1-amino-2-([3-(4-morpholino)propyl]amino)imidazoline;
20 1-amino-2-([3-(4-methylpiperazin-1-yl)propyl]amino)imidazoline;
1-amino-2-([3-(dimethylamino)propyl]amino)imidazoline;
1-amino-2-([3-ethoxypropyl]amino)imidazoline;
1-amino-2-([3-(1-imidazolyl)propyl]amino)imidazoline;
25 1-amino-2-(2-methoxyethylamino)-2-imidazoline;
1-amino-2-(3-isopropoxypropylamino)-2-imidazoline;
1-amino-2-(3-methylthiopropylamino)-2-imidazoline;
1-amino-2-[3-(1-piperidino)propylamino]imidazoline;
1-amino-2-[2,2-dimethyl-3-(dimethylamino)propylamino]-2-imidazoline;
30 1-amino-2-(neopentylamino)-2-imidazoline;
and the biocompatible and pharmaceutically acceptable salts thereof.

35 The above compounds are capable of inhibiting the formation of advanced glycosylation endproducts on target proteins. The cross-linking of the protein to form the

advanced glycosylation endproduct contributes to the entrapment of other proteins and results in the development in vivo of conditions such as reduced elasticity and wrinkling of the skin, certain kidney
5 diseases, atherosclerosis, osteoarthritis and the like. Similarly, plant material that undergoes nonenzymatic browning deteriorates and, in the case of foodstuffs, become spoiled or toughened and, consequently, inedible. Thus, the compounds employed in accordance with this
10 invention inhibit this late stage Maillard effect and intervene in the deleterious changes described above.

The rationale of the present invention is to use agents which block the post-glycosylation step, i.e., the
15 formation of fluorescent chromophores such as that identified in Pongor, et al., supra and Farmer et al., supra, among others, the presence of which chromophores is associated with, and leads to adverse sequelae of diabetes and aging. An ideal agent would prevent the
20 formation of the chromophore and its associated cross-links of proteins to proteins and trapping of proteins on the other proteins, such as occurs in arteries and in the kidney.

25 The chemical nature of the early glycosylation products with which the compounds of the present invention are believed to react, is speculative. Early glycosylation products with carbonyl moieties that are involved in the formation of advanced glycosylation endproducts, and that
30 may be blocked by reaction with the compounds of the present invention, have been postulated. In one case, the reactive carbonyl moieties of Amadori products or their further condensation, dehydration and/or rearrangement products, may condense to form advanced
35 glycosylation endproducts. Another proposed mechanism is the formation of reactive carbonyl compounds, containing one or more carbonyl moieties (such as glycolaldehyde,

glyc aldehyde or 3-deoxyglucosone) from the cleavage of Amadori or other early glycosylation endproducts (see, for example, Gottschalk, A. (1972) in *The Glycoproteins* (Gottschalk, A., ed) Part A, pp. 141-157, Els vier

- 5 Publishing Co., New York; Reynolds, T.M. (1965) Adv. Food Res., 14, pp. 167-283), and by subsequent reactions with an amine or Amadori product to form carbonyl containing advanced glycosylation products such as the alkylformyl-glycosylpyrroles described by Farmer et al, supra.

10

Several investigators have studied the mechanism of advanced glycosylation product formation. In vitro studies by Eble et al., (1983), "Nonenzymatic Glucosylation and Glucose-dependent Cross-linking of

- 15 Protein", J. Biol. Chem., 258:9406-9412, concerned the cross-linking of glycosylated protein with nonglycosylated protein in the absence of glucose. Eble et al. sought to elucidate the mechanism of the Maillard reaction and accordingly conducted controlled initial
20 glycosylation of RNAase as a model system, which was then examined under varying conditions. In one aspect, the glycosylated protein material was isolated and placed in a glucose-free environment and thereby observed to determine the extent of cross-linking.

25

Eble et al. thereby observed that cross-linking continued to occur not only with the glycosylated protein but with non-glycosylated proteins as well. One of the observations noted by Eble et al. was that the reaction

- 30 between glycosylated protein and the protein material appeared to occur at the location on the protein chain of the amino acid lysine. Confirmatory experimentation conducted by Eble et al. in this connection demonstrated that free lysine would compete with the lysine on RNAase
35 for the binding of glycosylated protein. Thus, it might be inferred from these data that lysine may serve as an inhibitor of advanced glycosylation; however, this

conclusion and the underlying observations leading to it should be taken in the relatively limited context of the model system prepared and examined by Eble et al.

Clearly, Eble et al. does not appreciate, nor is there a
5 suggestion therein, of the discoveries that underlie the present invention, with respect to the inhibition of advanced glycosylation of proteins both in vitro and in vivo.

10 The experiments of Eble et al. do not suggest the reactive cleavage product mechanism or any other mechanism in the in vivo formation of advanced glycosylation endproducts in which glucose is always present. In fact, other investigators support this
15 mechanism to explain the formation of advanced glycosylated endproducts in vivo (see for example Hayase et al, 1989, supra; Sell and Monnier, 1989, supra; Oimomi et al., Agric. Biol. Chem., 53(6):1727-1728 (1989); and Diabetes Research and Clinical Practice, 6:311-313
20 (1989). Accordingly, the use of lysine as an inhibitor in the Eble et al. model system has no bearing upon the utility of the compounds of the present invention in the inhibition of advanced glycosylated endproducts formation in the presence of glucose in vivo, and the amelioration
25 of complications of diabetes and aging.

The compositions useful in the present invention comprise or contain agents capable of reacting with the active carbonyl intermediate of an early glycosylation product.

30 Suitable agents are the compounds of Formula I of the present invention.

The present invention likewise relates to methods for inhibiting the formation of advanced glycosylation
35 endproducts, which comprise contacting the target proteins with a composition of the present invention. In the instance where the target proteins are contained in

foodstuffs, whether of plant or animal origin, these foodstuffs could have applied to them by various conventional means a composition containing the present agents.

5

In the food industry, sulfites were found years ago to inhibit the Maillard reaction and are commonly used in processed and stored foods. Recently, however, sulfites in food have been implicated in severe and even fatal reactions in asthmatics. As a consequence, the sulfite treatment of fresh fruits and vegetables has been banned. The mechanism for the allergic reaction is not known. Accordingly, the present compositions and agents offer a nontoxic alternative to sulfites in the treatment of foods in this manner.

As is apparent from a discussion of the environment of the present invention, the present methods and compositions hold the promise for arresting the aging of key proteins both in animals and plants, and concomitantly, conferring both economic and medical benefits as a result thereof. In the instance of foodstuffs, the administration of the present composition holds the promise for retarding food spoilage thereby making foodstuffs of increased shelf life and greater availability to consumers. Replacement of currently-used preservatives, such as sulfur dioxide known to cause allergies and asthma in humans, with non-toxic, biocompatible compounds is a further advantage of the present invention.

The therapeutic implications of the present invention relate to the arrest of the aging process which has, as indicated earlier, been identified in the aging of key proteins by advanced glycosylation and cross-linking. Thus, body proteins, and particularly structural body proteins, such as collagen, elastin, lens proteins, nerve

proteins, kidney glomerular basement membranes and other extravascular matrix components would all benefit in their longevity and operation from the practice of the present invention. The present invention thus reduces
5 the incidence of pathologies involving the entrapment of proteins by cross-linked target proteins, such as retinopathy, cataracts, diabetic kidney disease, glomerulosclerosis, peripheral vascular disease, arteriosclerosis obliterans, peripheral neuropathy,
10 stroke, hypertension, atherosclerosis, osteoarthritis, periarticular rigidity, loss of elasticity and wrinkling of skin, stiffening of joints, glomerulonephritis, etc. Likewise, all of these conditions are in evidence in patients afflicted with diabetes mellitus. Thus, the
15 present therapeutic method is relevant to treatment of the noted conditions in patients either of advanced age or those suffering from one of the mentioned pathologies.

Protein cross-linking through advanced glycosylation
20 product formation can decrease solubility of structural proteins such as collagen in vessel walls (see Brownlee et al., Science, 232, pp. 1629-1632, (1986)), and can also trap serum proteins, such as lipoproteins to the collagen. Also, this may result in increased
25 permeability of the endothelium and consequently covalent trapping of extravasated plasma proteins in subendothelial matrix, and reduction in susceptibility of both plasma and matrix proteins to physiologic degradation by enzymes. (See Brownlee et al., Diabetes,
30 35, Suppl. 1, p. 42A (1986)). For these reasons, the progressive occlusion of diabetic vessels induced by chronic hyperglycemia has been hypothesized to result from excessive formation of glucose-derived cross-links. Such diabetic macrovascular changes and microvascular
35 occlusion can be effectively prevented by chemical inhibition of advanced glycosylation product formation

utilizing a composition and the methods of the present invention.

Studies indicate that the development of chronic diabetic damage in target organs is primarily linked to hyperglycemia so that tight metabolic control would delay or even prevent end-organ damage. See Nicholls et al., Lab. Invest., 60, No. 4, p. 486 (1989), which discusses the effects of islet isografting and aminoguanidine in murine diabetic nephropathy. These studies further evidence that aminoguanidine diminishes aortic wall protein cross-linking in diabetic rats and confirm earlier studies by Brownlee et al., Science, 232, pp. 1629-1632 (1986) to this additional target organ of complication of diabetes. Also, an additional study showed the reduction of immunoglobulin trapping in the kidney by aminoguanidine (Brownlee et al., Diabetes, 35, Suppl. 1, p. 42A (1986)).

Further evidence in the streptozotocin-diabetic rat model that aminoguanidine administration intervenes in the development of diabetic nephropathy was presented by Brownlee et al., 1988, supra, with regard to morphologic changes in the kidney which are hallmarks of diabetic renal disease. These investigators reported that the increased glomerular basement membrane thickness, a major structural abnormality characteristic of diabetic renal disease, was prevented with aminoguanidine.

Taken together, these data strongly suggest that inhibition of the formation of advanced glycosylation endproducts (AGEs), by the teaching of the present invention, may prevent late, as well as early, structural lesions due to diabetes, as well as changes during aging caused by the formation of AGE's.

Diabetes-induced changes in the deformability of red blood cells, leading to more rigid cell membranes, is another manifestation of cross-linking and aminoguanidine has been shown to prevent it in vivo. In such studies, New Zealand White rabbits, with induced, long-term diabetes are used to study the effects of a test compound on red blood cell (RBC) deformability (df). The test compound is administered at a rate of 100 mg/kg by oral gavage to diabetic rabbits (Brown et al., Presentation of Abstract for Association for Academic Minority Physicians, Annual Scientific Meeting (1989)).

Increased cross-linking of collagen in diabetic rats has shown to be prevented by aminoguanidine. Oxlund and Andreassen, "The increase in biochemical and biomechanical stability of collagen in diabetic rats is prevented by aminoguanidine treatment", European Association for the Study of Diabetes, Twenty-fifth Annual Meeting, p. 525A, Abstract No. 371, 1989 showed the effect when thermal stability of tendon fibers was assessed by breaking time in a urea bath, as well as mechanical strength. Soulis et al., "Aminoguanidine reduces tissue fluorescence but not albuminuria in diabetic rats". NIH Conference on the Maillard Reaction in Aging, Diabetes, and Nutrition, Bethesda, Maryland, September 22-23, 1988, page 30) showed the same effect on collagen in the aorta, measured by fluorescence and solubility.

Giambione and Brownlee, "Aminoguanidine Treatment Normalizes Increased Steady-state Levels of Laminin B1 mRNA in Kidneys of Long-term Streptozotocin-diabetic Rats" Diabetes, 38, Supplement 2:83A Forty-ninth Annual Meeting, American Diabetes Association (1989) showed that aminoguanidine treatment to diabetic rats prevents the diabetes-induced increase in laminin B₁ mRNA in the kidney. This indicates that aminoguanidine may prevent

overproduction of matrix, which leads to basement membran thickening and morphologic and functional deterioration of vasculatur in kidneys and other organs.

- 5 A further consequence of diabetes is the hyperglycemia-induced matrix bone differentiation resulting in decreased bone formation usually associated with chronic diabetes. In animal models, diabetes reduces matrix-induced bone differentiation by 70% (Am. J. Phys., 238
10 (1980)).

In the instance where the compositions of the present invention are utilized for in vivo or therapeutic purposes, it may be noted that the compounds or agents
15 used therein are biocompatible. Pharmaceutical compositions may be prepared with a therapeutically effective quantity of the agents or compounds of the present invention and may include a pharmaceutically acceptable carrier, selected from known materials
20 utilized for this purpose. Such compositions may be prepared in a variety of forms, depending on the method of administration. Also, various pharmaceutically acceptable addition salts of the compounds of Formula I may be utilized.

25 A liquid form would be utilized in the instance where administration is by intravenous, intramuscular or intraperitoneal injection. When appropriate, solid dosage forms such as tablets, capsules, or liquid dosage
30 formulations such as solutions and suspensions, etc., may be prepared for oral administration. For topical or dermal application to the skin or eye, a solution, a lotion or ointment may be formulated with the agent in a suitable vehicle such as water, ethanol, propylene
35 glycol, perhaps including a carrier to aid in penetration into the skin or eye. For example, a topical preparation could include up to about 10% of the compound of Formula

I. Other suitable forms for administration to other body tissues are also contemplated.

In the instance where the present method has therapeutic application, the animal host intended for treatment may have administered to it a quantity of one or more of the agents, in a suitable pharmaceutical form.

Administration may be accomplished by known techniques, such as oral, topical and parenteral techniques such as intradermal, subcutaneous, intravenous or intraperitoneal injection, as well as by other conventional means. Administration of the agents may take place over an extended period of time at a dosage level of, for example, up to about 25 mg/kg.

15

As noted earlier, the invention also extends to a method of inhibiting the discoloration of teeth resulting from nonenzymatic browning in the oral cavity which comprises administration to a subject in need of such therapy an amount effective to inhibit the formation of advanced glycosylation endproducts of a composition comprising an agent of the structural Formula I.

The nonenzymatic browning reaction which occurs in the oral cavity results in the discoloration of teeth.

Presently used anti-plaque agents accelerate this nonenzymatic browning reaction and further the staining of the teeth. Recently, a class of cationic anti-microbial agents with remarkable anti-plaque properties have been formulated in oral rinses for regular use to kill bacteria in the mouth. These agents, the cationic antiseptics, include such agents as alexidine, cetyl pyridinium chloride, chlorhexidine gluconate, hexetidine, and benzalkonium chloride.

35

Tooth staining by chlorhexidine and other anti-plaque agents apparently results from the enhancement of the

Maillard reaction. Nordbo, J. Dent. Res., 58, p. 1429 (1979) reported that chlorhexidine and benzalkonium chloride catalyze browning reactions in vitro. Chlorhexidine added to mixtures containing a sugar derivative and a source of amino groups underwent increased color formation, attributed to the Maillard reaction. It is also known that use of chlorhexidine results in an increased dental pellicle. Nordbo proposed that chlorhexidine resulted in tooth staining in two ways: first, by increasing formation of pellicle which contains more amino groups, and secondly, by catalysis of the Maillard reaction leading to colored products.

In accordance with this method, the compounds of Formula I are formulated into compositions adapted for use in the oral cavity. Particularly suitable formulations are oral rinses and toothpastes incorporating the active agent.


In the practice of this invention, conventional formulating techniques are utilized with nontoxic, pharmaceutically acceptable carriers typically utilized in the amounts and combinations that are well-known for the formulation of such oral rinses and toothpastes.

The agent of Formula I is formulated in compositions in an amount effective to inhibit the formation of advanced glycosylation endproducts. This amount will, of course, vary with the particular agent being utilized and the particular dosage form, but typically is in the range of 0.01% to 1.0%, by weight, of the particular formulation.

Additionally, since the agents of the aforesaid method are concentrated in the salivary glands upon oral ingestion or parenteral administration, they can be so administered. This concentration in the salivary glands results in their secretion into saliva, the net result being that they are functionally placed in the oral


cavity where they can effect their desired method. For such administration, the particular agent can be formulated in any conventional oral or parenteral dosage form. A particularly desirable dosage form is the
5 incorporation of the agent into a vitamin tablet or fluoride tablet so as to maximize patient, and particularly juvenile patient, compliance.

The novel compounds of Formula I of the present invention
10 are conveniently prepared by reacting the appropriate starting material of the formula



15

wherein n and R₁ are as hereinbefore defined and Y is an appropriate leaving group with an amino compound of the formula



wherein R₂ is as hereinbefore defined, in a protic solvent. Typically, the solvent is an alcohol such as ethanol or isopropanol. The reaction is conducted at temperatures from room temperature to reflux (depending
25 upon the chosen solvent). Typical reaction times vary from 1-12 hours. Appropriate leaving groups are those such as methylthio groups, chloro, bromo or iodo atoms, and the like.

30 The starting materials of Formulae II and III are generally known from the literature (see, for instance, U.S. Patent No. 4,908,446). However, in the case wherein R₁ is a hydroxyethyl group, the intermediate of Formula II is conveniently prepared by reaction of either
35 (hydroxyethyl)ethylenediamine (for n=1) or 2-(3-aminopropylamino) ethanol (for n=2) with carbon disulfide. The resulting 1-(2-hydroxyethyl)-2-

imidazolinethione (n=1) or 1-(2-hydroxyethyl)-3,4,5,6-tetrahydropyrimidine-2-thione (n=2) is then reacted to with methyl methanesulfonate to form the necessary intermediate of Formula II.

5

The following examples are illustrative of the compounds, compositions and methods of the present invention.

EXAMPLE I

10

- 2-(3-Aminopropylamino)ethanol (118 ml) is dissolved in 1:1 ethyl alcohol-water (340 ml) and heated to 40-50°C. Carbon disulfide (60 ml) is added dropwise over a period of about 15 minutes. An exothermic reaction occurs after about half of the amount of carbon disulfide is added. After the addition of all the carbon disulfide, the mixture is refluxed for about 1 hour. Concentrated hydrochloric acid (8 ml) is then added, and the reaction mixture is refluxed overnight. After cooling in an ice bath, the crystalline solid which separates is filtered, washed with isopropyl alcohol and t-butyl methyl ether, and dried to give 129-4g of 1-(2-hydroxyethyl)-3,4,5,6-tetrahydropyrimidine-2-thione, melting point 112-114°C.
- 25 Then, 1-(2-hydroxyethyl)-3,4,5,6-tetrahydropyrimidine-2-thione (121.2g) and methyl methanesulfonate (91.51g) are heated at reflux in ethyl alcohol (200 ml) for about 2 hours and then allowed to cool to room temperature. The mixture was diluted with t-butyl methyl ether (2 liters).
- 30 An oil separates which crystallizes on keeping in freezer at -20°C. Filtration and drying yields 145.7 g of 1-(2-hydroxyethyl)-2-methylthio-3,4,5,6-tetrahydropyrimidine mesylate, melting point 61.7-62.2°C.
- 35 1-(2-hydroxyethyl)-2-methylthio-3,4,5,6-tetrahydropyrimidine mesylate (87.2g) is suspended in ethyl alcohol (150 ml) and treated with anhydrous hydrazine (22 mL).

The mixture becomes clear within a few minutes. It is stirred at room temperature overnight and then diluted with t-butyl methyl ether (2 liters). The solution is kept in the freezer at -20°C until the solid separates, filters and dries. Recrystallization from isopropyl alcohol and t-butyl methyl ether gives 68.12g of 1-(2-hydroxyethyl)-2-hydrazino-3,4,5,6-tetrahydropyrimidine mesylate, melting point 82.2-84.4°C.

10

EXAMPLE 2

(Hydroxyethyl)ethylenediamine (25 ml) is dissolved in 1:1 ethyl alcohol-water (85 mL) and heated to 40-50°C. Carbon disulfide (16.5 ml) is added dropwise over a period of about 15 minutes. After about half of the amount is added, the exothermic reaction starts and the reaction mixture solidifies. After the addition of all of the carbon disulfide, the mixture is refluxed gently for about 1 hour. Concentrated hydrochloric acid (2 ml) is then added and the reaction mixture is refluxed overnight. The solid which separates after the addition of carbon disulfide redissolves. The solution is cooled in an ice bath, and the solid separates, is filtered out, washed well with isopropyl alcohol and t-butyl methyl ether and dried to give 23.3g of 1-(2-hydroxyethyl)-2-imidazolinethione, melting point 137-138°C.

Twenty grams of 1-(2-hydroxyethyl)-2-imidazolinethione and methyl methanesulfonate (12.75 ml) are dissolved in ethyl alcohol (90 mL) and refluxed for 2 hours. The mixture is cooled to room temperature and diluted with t-butyl methyl ether (1 liter). An oil separates which solidifies on keeping the mixture in the freezer at -20°C for a few days. The solid is then filtered, washed with butyl methyl ether and dried to give 1-(2-hydroxyethyl)-2-methylthioimidazoline mesylate, melting point 78.9-81.5°C.

1-(2-Hydroxyethyl)-2-methylthioimidazoline mesylate (35g, 0.136 mole) is suspended in ethyl alcohol (80 ml) and treated with anhydrous hydrazine (9.3 ml, 0.296 mole). The mixture became clear immediately. The solution is stirred at room temperature overnight and then diluted with t-butyl methyl ether (1 liter). On storage of the mixture in the freezer at -20°C, crystals separated, which are filtered, washed well with t-butyl methyl ether and dried. Recrystallization from isopropyl alcohol and t-butyl methyl ether gives 1-(2-hydroxyethyl)-2-hydrazinoimidazoline mesylate, melting point 85-88°C.

EXAMPLE 3

1-Amino-2-methylthio-2-imidazoline (U.S. Patent No. 4,908,446) (3.03g) and isopropanol (7.5 ml) were placed in a 25 ml round bottom flask, and 2-hydroxyethylhydrazine (1.52g) was added dropwise. The mixture is heated to about 40°C to give a solution. The heat is removed and stirring is continued at 25°C overnight. The deposited crystals are filtered out, washed with isopropanol and air dried. Recrystallization from isopropanol gives 0.74g of 1-amino-2-[2-(2-hydroxyethyl)-hydrazino]2-imidazoline tosylate as colorless crystals, melting point 26.9-127.2°.

EXAMPLE 4

1-Amino-2-methylthio-2-imidazoline tosylate (3.03g) and isopropanol (7.5 ml) are placed in a 25 ml round bottom flask, then 2-aminoethanol (1.22g) is added. The mixture is heated to about 40°C to give a solution. After stirring overnight at 25°C, the mixture is concentrated to a thick colorless oil. Crystals were formed upon storage at -20°C. Trituration with 10 ml isopropanol and filtration gives 2.68g (84.8%) of 1-amino-2-(2-

hydroxyethyl)-2-imidazoline tosylate as colorless crystals with mp 91.8-92.7°C.

EXAMPLE 5

5

1-Amino-2-methylthio-2-imidazoline tosylate (1g) and 4-(2-aminoethyl)morpholine (0.47g) are dissolved in ethyl alcohol (10 ml) and refluxed overnight. The reaction mixture is cooled to room temperature and diluted with t-butyl methyl ether (75 ml). The white solid which separates, is filtered, washed well with t-butyl methyl ether, and dried. Crystallization from isopropyl alcohol gives 940 mg of colorless crystals of 1-amino-2-(4-[2-aminoethyl]morpholino)-2-imidazoline tosylate, melting point 139.9-141°C.

Following analogous procedures, the following aminoalkyl imidazoline derivatives are prepared (substituting for 4-(2-aminoethyl)morpholine the following reagents:

20

From 4-(3-aminopropyl)morpholine, the compound 1-amino-2-(4-[3-aminopropyl]morpholino)-2-imidazoline tosylate, melting point 154-155°C.

25 From 1-(3-aminopropyl)-4-methylpiperazine, the compound 1-amino-2-(1-[3-aminopropyl]-4-methylpiperazino)-2-imidazoline tosylate, melting point 127-129°C.

From 3-dimethylaminopropylamine, the compound 1-amino-2-[3-(dimethylamino)propylamino]-2-imidazoline tosylate, melting point 112-114°C.

From 3-ethoxypropylamine, the compound 1-amino-2-(3-ethoxypropylamino)-2-imidazoline tosylate, melting point 106-107°C.

From 1-(3-aminopropyl)imidazol , the compound 1-amino-2-[3-(1-imidazolyl)propyl]amino-2-imidazoline tosylate, melting point 123-125°C.

- 5 From 2-methoxyethylamine, the compound 1-amino-2-(2-methoxyethyl)amino-2-imidazoline tosylate, melting point 94.2-97.2°.

- 10 From 3-isopropoxypropylamine, the compound 1-amino-2-(3-methylthiopropylamino)-2-imidazoline tosylate, melting point 98-100°C.

- 15 From 1-amino-3-(N-piperidino)propane, the compound 1-amino-2-[1-amino-3-(N-piperidino)propyl]-2-imidazoline tosylate, melting point 137-139.7°.

- 20 From N,N,2,2-tetramethyl-1,3-propanediamine, the compound 1-amino-2-(N,N,2,2-tetramethyl-1,3-propanediamino)-2-imidazoline tosylate, melting point 101.9-102.9°.

From neopentylamine, the compound 1-amino-2-(neopentylamino)-2-imidazoline tosylate, melting point 166.4-167.5°C.

25

EXAMPLE 6

- The following method was used to evaluate the ability of the compounds of the present invention to inhibit glucose-mediated development of fluorescence of bovine serum albumin (BSA), a measure of cross-linking.
- 30

Compounds were incubated under aseptic conditions at a concentration of 1 mM with 400 mM glucose and 100 mg/mL BSA in a 1.5 M sodium phosphate buffer, pH 7.4.

- 35 Samples of the incubation mixture were taken immediately and after 1 week incubation at 37°C for measurement of fluorescence. For each test compound, control

incubations in buffer were made of compound alone (C), compound plus glucose (G+C), and compound plus BSA (B+C). An additional set of incubations of glucose and BSA (B+G) were prepared as the baseline controls against which were
 5 measured the ability of the compounds to inhibit. Each incubation was made in triplicate.

Fluorescence (excitation, 370 nm; emission, 440 nm) was measured on each sample after a 100-fold dilution in
 10 distilled water.

The % inhibition of browning of each test compound was calculated as follows. Each ΔF represents the fluorescence measurement of that sample after 1 week
 15 incubation less its fluorescence before incubation.

% inhibition =

$$20 \quad \frac{F_{B+G} - [F_{B+G+C} - (F_C + F_{G+C} + F_{B+C})]}{F_{B+G}} \times 100$$

where B=BSA, G=glucose, and C=test compound.

Percent inhibition of browning by various test compounds
 25 at 1 mM:

	0%	no inhibitor
	68.1%	1-amino-2-[2-(2-hydroxyethyl)hydrazino]-2-imidazoline tosylate;
	61%	1-amino-2-(2-hydroxyethylamino)-2-imidazoline tosylate;
30	38.5%	1-(2-hydroxyethyl)-2-hydrazino-1,4,5,6-tetrahydropyrimidine methanesulfonate;
	45.1%	1-(2-hydroxyethyl)-2-hydrazino-2-imidazoline methanesulfonate;
35	5.9%	1-amino-2-([3-(4-morpholino)propyl]amino)imidazoline tosylate;

- 16.7% 1-amino-2-([3-(dimethylamino)propyl]
amino)imidazoline tosylate;
19.9% 1-amino-2-([3-(1-imidazolyl)propyl]
amino)imidazoline tosylate;

5

The above experiments suggest that this type of drug therapy may have benefit in reducing the pathology associated with the advanced glycosylation of proteins and the formation of cross-links between proteins and other macromolecules. Drug therapy may be used to prevent the increased trapping and cross-linking of proteins that occurs in diabetes and aging which leads to sequelae such as retinal damage, and extra-vascularly, damage to tendons, ligaments and other joints. This therapy might retard atherosclerosis and connective tissue changes that occur with diabetes and aging. Both topical, oral, and parenteral routes of administration to provide therapy locally and systemically are contemplated.

20

EXAMPLE 7

<u>Tablet</u>	<u>mg/tablet</u>
Compound of Formula I	50
25 Starch	50
Mannitol	75
Magnesium stearate	2
Stearic acid	5

30 The compound, a portion of the starch and the lactose are combined and wet granulated with starch paste. The wet granulation is placed on trays and allowed to dry overnight at a temperature of 45°C. The dried granulation is comminuted in a comminutor to a particle
35 size of approximately 20 mesh. Magnesium stearate, stearic acid and the balance of the starch are added and the entire mix blended prior to compression on a suitable

tablet press. The tablets are compressed at a weight of 232 mg. using a 11/32" punch with a hardness of 4 kg. These tablets will disintegrate within a half hour according to the method described in USP XVI.

5

EXAMPLE 8

<u>Lotion</u>	<u>mg/g</u>
Compound of Formula I	1.0
10 Ethyl alcohol	400.0
Polyethylene glycol 400	300.0
Hydroxypropyl cellulose	5.0
Propylene glycol	to make 1.0 g

15

EXAMPLE 8

<u>Oral Rinse</u>	
Compound of Formula I:	1.4 %
Chlorhexidine gluconate	0.12 %
20 Ethanol	11.6 %
Sodium saccharin	0.15 %
FD&C Blue No. 1	0.001%
Peppermint Oil	0.5 %
Glycerine	10.0 %
25 Tween 60	0.3 %
Water to	100 %

EXAMPLE 9

<u>30 Toothpaste</u>	
Compound of Formula I:	5.5 %
Sorbitol, 70% in water	25 %
Sodium saccharin	0.15 %
Sodium lauryl sulfate	1.75 %
35 Carbopol 934, 6% dispersion in water	15 %
Oil of Spearmint	1.0 %
Sodium hydroxide, 50% in water	0.76 %

Dibasic calcium phosphate dihydrate	45	%
Water to	100	%

EXAMPLE 11

5

To further study the ability of inhibitors of nonenzymatic browning to prevent the discoloration of protein on a surface, such as that which occurs on the tooth surface, the following surface browning experiment is performed. As a substitute for a pellicle-covered tooth surface, unexposed and developed photographic paper is used to provide a fixed protein (gelatin, i.e., collagen) surface on a paper backing. Five millimeter circles are punched and immersed for one week at 50°C in a solution of 100 mM glucose-6-phosphate in a 0.5 M phosphate buffer, pH 7.4, containing 3 mM sodium azide. Glucose-6-phosphate is a sugar capable of participating in nonenzymatic browning at a more rapid rate than glucose. In addition to the glucose-6-phosphate, chlorhexidine and/or a compound of Formula I are included. After incubation, the gelatin/paper disks are rinsed with water, observed for brown color, and photographed.

Incubation of the disks in glucose-6-phosphate alone shows slight brown color versus disks soaked in buffer alone. Inclusion of chlorhexidine (in the form of Peridex® at a final concentration of 0.04% chlorhexidine) shows significant browning. Addition of a compound of Formula I to the chlorhexidine inhibits browning of the gelatin, as does inclusion of a compound of Formula I in the absence of chlorhexidine.


The slight brown color formed by the action of glucose-6-phosphate on the gelatin surface alone and its prevention by a compound of Formula I demonstrates the utility of the present invention in preventing non enzymatic browning

of tooth surfaces. The enhanced browning in the presence of chlorhexidine and its prevention with a compound of Formula I demonstrates the utility of the present invention in preventing the anti-plaque agent-enhanced nonenzymatic browning which occurs with chlorhexidine.

This invention may be embodied in other forms or carried out in other ways without departing from the spirit or essential characteristics thereof. The present disclosure is therefore to be considered as in all respects illustrative and not restrictive, the scope of the invention being indicated by the appended Claims, and all changes which come within the meaning and range of equivalency are intended to be embraced therein.

WHAT IS CLAIMED IS:

1 1. A compound of the formula



2
3 wherein

4 n is 1 or 2;

5 R₁ is a hydroxyethyl or an amino group;

6 R₂ is an amino, a hydroxylower alkylamino, a lower
7 alkyl group, or a group of the formula

8 alk-Y

9 wherein alk is a lower alkylene group and Y is
10 selected from the group consisting of hydroxy, lower
11 alkoxy, lower alkylthio and heterocyclic groups which
12 contain 4-7 ring members and 1-3 heteroatoms;

13 with the proviso that when R₁ is a hydroxy ethyl
14 group, then R₂ is an amino group;

15 and the biocompatible and pharmaceutically
16 acceptable salts thereof.

1 2. A compound according to Claim 1 wherein R₁ is a
2 hydroxyethyl group.

1 3. A compound according to Claim 2 wherein n is 2.

1 4. A compound according to Claim 3 which is 1-(2-
2 hydroxyethyl)-2-hydrazino-1,4,5,6-tetrahydropyrimidine
3 methanesulfonate or another pharmaceutically acceptable
4 salt thereof.

1 5. A compound according to Claim 2 wherein n is 1.

1 6. A compound according to Claim 5 which is 1-(2-
2 hydroxyethyl)-2-hydrazino-2-imidazoline methanesulfonate

3 or another pharmaceutically acceptable salt thereof.

1 7. A compound according to Claim 1 wherein R_1 is an
2 amino group.

1 8. A compound according to Claim 7 wherein R_2 is a
2 hydroxylower alkyl group.

1 9. A compound according to Claim 8 which is 1-amino-2-
2 [2-(2-hydroxyethyl)hydrazino]-2-imidazoline tosylate or
3 another pharmaceutically acceptable salt thereof.

1 10. A compound according to Claim 7 wherein R_2 is a lower
2 alkyl group.

1 11. A compound according to Claim 10 which is 1-amino-2-
2 (neopentylamino)-2-imidazoline tosylate or another
3 pharmaceutically acceptable salt thereof.

1 12. A compound according to Claim 7 wherein R_2 is a group
2 of the formula
3 alk-Y
4 wherein alk is a lower alkylene group and Y is selected
5 from the group consisting of hydroxy, lower alkoxy, lower
6 alkyl thio, lower alkylamino and heterocyclic groups
7 which contain 4-7 ring members and 1-3 heteroatoms.

1 13. A compound according to Claim 12 which is 1-amino-2-
2 (2-hydroxyethylamino)-2-imidazoline tosylate or another
3 pharmaceutically acceptable salt thereof.

1 14. A compound according to Claim 12 which is 1-amino-2-
2 [(3-ethoxypropyl)amino]imidazoline tosylate or another
3 pharmaceutically acceptable salt thereof.

1 15. A compound according to Claim 12 which is 1-amino-2-
2 (2-methoxyethylamino)-2-imidazoline tosylate or another
3 pharmaceutically acceptable salt thereof.

1 16. A compound according to Claim 12 which is 1-amino-2-
2 (3-isopropoxypropyl amino)-2-imidazoline tosylate or
3 another pharmaceutically acceptable salt thereof.

1 17. A compound according to Claim 12 which is 1-amino-2-
2 (3-methylthiopropylamino)-2-imidazoline tosylate or
3 another pharmaceutically acceptable salt thereof.

1 18. A compound according to Claim 12 which is 1-amino-2-
2 ([3-(dimethylamino)propyl]amino)imidazoline tosylate or
3 another pharmaceutically acceptable salt thereof.

1 19. A compound according to Claim 12 which is 1-amino-2-
2 [2,2-dimethyl-3-(dimethylamino)propylamino]-2-imidazoline
3 tosylate or another pharmaceutically acceptable salt
4 thereof.

5

6 20. A compound according to Claim 12 which is 1-amino-2-
7 ([2-(4-morpholino)ethyl]amino)imidazoline tosylate or
8 another pharmaceutically acceptable salt thereof.


1 21. A compound according to Claim 12 which is 1-amino-2-
2 (2-([3-(4-morpholino)propyl]amino)imidazoline tosylate or
3 another pharmaceutically acceptable salt thereof.

1 22. A compound according to Claim 12 which is 1-amino-2-
2 ([3-(4-methylpiperazin-1-yl)propyl]amino)imidazoline
3 tosylate or another pharmaceutically acceptable salt
4 thereof.

1 23. A compound according to Claim 12 which is 1-amino-2-
2 ([3-(1-imidazolyl)propyl]amino)imidazoline tosylate or
3 another pharmaceutically acceptable salt thereof.

1 24. A compound according to Claim 12 which is 1-amino-2-
 2 [3-(1-piperidino)propylamino]imidazoline toluenesulfonate
 3 or another pharmaceutically acceptable salt thereof.

1 25. A composition for inhibiting the advanced
 2 glycosylation of a target protein comprising an effective
 3 amount of a compound selected from the group consisting
 4 of compounds of the formula



6 wherein

7 n is 1 or 2;

8 R₁ is a hydroxyethyl or an amino group;

9 R₂ is an amino, a hydroxylower alkylamino, a lower
 10 alkyl group, or a group of the formula


11 alk-Y

12 wherein alk is a lower alkylene group and Y is
 13 selected from the group consisting of hydroxy, lower
 14 alkoxy, lower alkylthio and heterocyclic groups which
 15 contain 4-7 ring members and 1-3 heteroatoms;

16 with the proviso that when R₁ is a hydroxy ethyl
 17 group, then R₂ is an amino group;

18 and the biocompatible and pharmaceutically
 19 acceptable salts thereof.

1 26. A pharmaceutical composition for administration to
 2 an animal to inhibit the advanced glycosylation of a
 3 target protein within said animal, comprising a
 4 pharmaceutically effective amount of a compound selected
 5 from the group consisting of compounds of the formula



7 wherein
8 n is 1 or 2;
9 R₁ is a hydroxyethyl or an amino group;
10 R₂ is an amino, a hydroxylower alkylamino, a lower
11 alkyl group, or a group of the formula
12 alk-Y
13 wherein alk is a lower alkylene group and Y is
14 selected from the group consisting of hydroxy, lower
15 alkoxy, lower alkylthio and heterocyclic groups which
16 contain 4-7 ring members and 1-3 heteroatoms;
17 with the proviso that when R₁ is a hydroxy ethyl
18 group, then R₂ is an amino group;
19 and the biocompatible and pharmaceutically
20 acceptable salts thereof.

1 27. The composition of Claim 26 wherein said compound
2 has the formula wherein R₁ is an hydroxyethyl group.

1 28. The composition of Claim 27 wherein said compound is
2 1-(2-hydroxyethyl)-2-hydrazino-1,4,5,6-
3 tetrahydropyrimidine methanesulfonate or another
4 pharmaceutically acceptable salt thereof.

1 29. The composition of Claim 27 wherein said compound is
2 1-(2-hydroxyethyl)-2-hydrazino-2-imidazoline
3 methanesulfonate or another pharmaceutically acceptable
4 salt thereof.

1 30. The composition of Claim 26 wherein said compound
2 has the formula wherein R₁ is an amino group.

1 31. The composition of Claim 30 wherein said compound is
2 1-amino-2-[2-(2-hydroxyethyl)hydrazino]-2-imidazoline -
3 tosylate or another pharmaceutically acceptable salt
4 thereof.

1 32. The composition of Claim 30 wherein said compound is
2 1-amino-2-(neopentylamino)-2-imidazoline tosylate or
3 another pharmaceutically acceptable salt thereof.

1 33. The composition of Claim 30 wherein said compound is
2 1-amino-2-(2-hydroxyethylamino)-2-imidazoline tosylate or
3 another pharmaceutically acceptable salt thereof.

4

1 34. The composition of Claim 30 wherein said compound is
2 1-amino-2-[(3-ethoxypropyl)amino]imidazoline tosylate or
3 another pharmaceutically acceptable salt thereof.

1 35. The composition of Claim 30 wherein said compound is
2 1-amino-2-(2-methoxyethylamino)-2-imidazoline tosylate or
3 another pharmaceutically acceptable salt thereof.

1 36. The composition of Claim 30 wherein said compound is
2 1-amino-2-(3-isopropoxypropylamino)-2-imidazoline
3 tosylate or another pharmaceutically acceptable salt
4 thereof.

1 37. The composition of Claim 30 wherein said compound is
2 1-amino-2-(3-methylthiopropylamino)-2-imidazoline
3 tosylate or another pharmaceutically acceptable salt
4 thereof.

1 38. The composition of Claim 30 wherein said compound is
2 1-amino-2-([3-(dimethylamino)propyl]amino)imidazoline
3 tosylate or another pharmaceutically acceptable salt
4 thereof.

1 39. The composition of Claim 30 wherein said compound is
2 1-amino-2-[2,2-dimethyl-3-(dimethylamino)propylamino]-2-
3 imidazoline tosylate or another pharmaceutically
4 acceptable salt thereof.

1 40. The composition of Claim 30 wherein said compound is
2 1-amino-2-([2-(4-morpholino)ethyl]amino)imidazoline
3 tosylate or another pharmaceutically acceptable salt
4 thereof.


1 41. The composition of Claim 30 wherein said compound is
2 1-amino-2-([3-(4-morpholino)propyl]amino)imidazoline
3 tosylate or another pharmaceutically acceptable salt
4 thereof.

1 42. The composition of Claim 30 wherein said compound is
2 1-amino-2-([3-(4-methylpiperazin-1-yl)propyl]
3 amino)imidazoline tosylate or another pharmaceutically
4 acceptable salt thereof.

1 43. The composition of Claim 30 wherein said compound is
2 1-amino-2-([3-(1-imidazolyl)propyl]amino)imidazoline
3 tosylate or another pharmaceutically acceptable salt
4 thereof.

1 44. The composition of Claim 30 wherein said compound is
2 1-amino-2-([3-(1-piperidino)propyl]amino)imidazoline
3 tosylate or another pharmaceutically acceptable salt
4 thereof.

1 45. A method for inhibiting the advanced glycosylation
2 of a target protein comprising contacting the target
3 protein with an effective amount of composition
4 comprising a compound selected from the group consisting
5 of compounds of the formula



8 wherein

9 n is 1 or 2;

10 R_1 is a hydroxyethyl or an amino group;

11 R_2 is an amino, a hydroxylower alkylamino, a lower
12 alkyl group, or a group of the formula

13 alk-Y


14 wherein alk is a lower alkylene group and Y is
15 selected from the group consisting of hydroxy, lower
16 alkoxy, lower alkylthio and heterocyclic groups which
17 contain 4-7 ring members and 1-3 heteroatoms;

18 with the proviso that when R_1 is a hydroxy ethyl
19 group, then R_2 is an amino group;

20 and the biocompatible and pharmaceutically
21 acceptable salts thereof.

1 46. A method for treating an animal to inhibit the
2 formation of advanced glycosylation endproducts of a
3 target protein within said animal, said method comprising
4 administering an effective amount of a pharmaceutical
5 composition, said pharmaceutical composition comprising a
6 compound selected from the group consisting of compounds
7 of the formula

8



9 wherein

10 n is 1 or 2;

11 R_1 is a hydroxyethyl or an amino group;

12 R_2 is an amino, a hydroxylower alkylamino, a lower
13 alkyl group, or a group of the formula

14 alk-Y

15 wherein alk is a lower alkylene group and Y is
16 selected from the group consisting of hydroxy, lower
17 alkoxy, lower alkylthio and heterocyclic groups which
18 contain 4-7 ring members and 1-3 heteroatoms;

19 with the proviso that when R₁ is a hydroxy ethyl
20 group, then R₂ is an amino group;
21 and the biocompatible and pharmaceutically
22 acceptable salts thereof.

1 47. The method of Claim 46 wherein said compound has the
2 formula wherein R₁ is a hydroxyethyl group.

1 48. The method of Claim 47 wherein said compound is
2 1-(2-hydroxyethyl)-2-hydrazino-1,4,5,6-
3 tetrahydropyrimidine methanesulfonate or another
4 pharmaceutically acceptable salt thereof.

1 49. The method of Claim 47 wherein said compound is 1-
2 (2-hydroxyethyl)-2-hydrazino-2-imidazoline
3 methanesulfonate or another pharmaceutically acceptable
4 salt thereof.

1 50. The method of Claim 47 wherein said compound has the
2 formula wherein R₁ is an amino group.

1 51. The method of Claim 47 wherein said compound is 1-
2 amino-2-[2-(2-hydroxyethyl)hydrazino]-2-imidazoline
3 tosylate or another pharmaceutically acceptable salt
4 thereof.

1 52. The method of Claim 47 wherein said compound is 1-
2 amino-2-(neopentylamino)-2-imidazoline tosylate or
3 another pharmaceutically acceptable salt thereof.

1 53. The method of Claim 47 wherein said compound is 1-
2 amino-2-(2-hydroxyethylamino)-2-imidazoline tosylate or
3 another pharmaceutically acceptable salt thereof.

1 54. The method of Claim 47 wherein said compound is 1-
2 amino-2-[(3-ethoxypropyl)amino]imidazoline tosylate or
3 another pharmaceutically acceptable salt thereof.

1 55. The method of Claim 47 wherein said compound is 1-
2 amino-2-(2-methoxyethylamino)-2-imidazoline tosylate or
3 another pharmaceutically acceptable salt thereof.

1 56. The method of Claim 47 wherein said compound is 1-
2 amino-2-(3-isopropoxypropylamino)-2-imidazoline tosylate
3 or another pharmaceutically acceptable salt thereof.

1 57. The method of Claim 47 wherein said compound is 1-
2 amino-2-(3-methylthiopropylamino)-2-imidazoline tosyltae
3 or another pharmaceutically acceptable salt thereof.

1 58. The method of Claim 47 wherein said compound is 1-
2 amino-2-([3-(dimethylamino)propyl]amino)imidazoline
3 tosylate or another pharmaceutically acceptable salt
4 thereof.

1 59. The method of Claim 47 wherein said compound is 1-
2 amino-2-[2,2-dimethyl-3-(dimethylamino)propylamino]-2-
3 imidazoline tosylate or another pharmaceutically
4 acceptable salt thereof.

1 60. The method of Claim 47 wherein said compound is 1-
2 amino-2-([2-(4-morpholino)ethyl]amino)imidazoline
3 tosylate or another pharmaceutically acceptable salt
4 thereof.

1 61. The method of Claim 47 wherein said compound is 1-
2 amino-2-([3-(4-morpholino)propyl]amino)imidazoline
3 tosylate or another pharmaceutically acceptable salt
4 thereof.


1 62. The method of Claim 47 wherein said compound is 1-
2 amino-2-([3-(4-methylpiperazin-1-yl)propyl]
3 amino)imidazoline tosylate or another pharmaceutically
4 acceptable salt thereof.

1 63. The method of Claim 47 wherein said compound is 1-
 2 amino-2-([3-(1-imidazolyl)propyl]amino)imidazoline
 3 tosylate or another pharmaceutically acceptable salt
 4 thereof.

1 64. The method of Claim 47 wherein said compound is 1-
 2 amino-2-([3-(1-piperidino)propyl]amino)imidazoline
 3 tosylate or another pharmaceutically acceptable salt
 4 thereof.

1 65. A method of inhibiting the discoloration of teeth
 2 resulting from non-enzymatic browning in the oral cavity
 3 which comprises administration of an amount effective to
 4 inhibit the formation of advanced glycosylation
 5 endproducts of a composition comprising a compound
 6 selected from the group consisting of compounds of the
 7 formula

8



9 wherein

10 n is 1 or 2;

11 R₁ is a hydroxyethyl or an amino group;

12 R₂ is an amino, a hydroxylower alkylamino, a lower
 13 alkyl group, or a group of the formula

14 alk-Y

15 wherein alk is a lower alkylene group and Y is
 16 selected from the group consisting of hydroxy, lower
 17 alkoxy, lower alkylthio and heterocyclic groups which
 18 contain 4-7 ring members and 1-3 heteroatoms;

19 with the proviso that when R₁ is a hydroxy ethyl
 20 group, then R₂ is an amino group;

21 and the biocompatible and pharmaceutically
 22 acceptable salts thereof.

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5 C07D239/18; C07D233/48;	A61K31/505; A01N43/54;	C07D239/14; A61K31/415; C07D233/52 A01N43/50
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	C07D ; A61K ; A01N	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category [*]	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	EP,A,0 158 020 (AMERICAN CYANAMID COMPANY) 16 October 1985 see the whole document ---	1-3,5
A	FR,A,1 162 631 (MONSANTO CANADA) 16 September 1958 ---	
<p>[*] Special categories of cited documents :¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
22 JULY 1992	11.08.92	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	DE BUYSER I.A.F.	

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. US 9201033
SA 58234**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 22/07/92

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0158020	16-10-85	US-A- 4574155	04-03-86
		AU-B- 578935	10-11-88
		AU-A- 3963485	12-09-85
		DE-A- 3507579	12-09-85
		JP-A- 60204768	16-10-85

FR-A-1162631		None	
